MabVax Therapeutics Holdings, Inc. announced the appointment of Jeffrey Eisenberg to the board of directors. Jeffrey Eisenberg served in a variety of senior management positions, including most recently as President, Chief Executive Officer and a board member of Noven Pharmaceuticals, Inc.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | +10.05% | +182.21% |
2020 | MabVax Therapeutics Holdings, Inc. Went Out of Business | CI |
2020 | Second Amended Liquidation Plan & Disclosure Statment Approved for MabVax Therapeutics Holdings, Inc. | CI |
1st Jan change | Capi. | |
---|---|---|
+182.21% | 213K | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-13.31% | 16.5B | |
+2.44% | 13.39B | |
+27.89% | 11.1B |
- Stock Market
- Equities
- MBVXQ Stock
- News MabVax Therapeutics Holdings, Inc.
- MabVax Therapeutics Holdings, Inc. Appoints Jeffrey Eisenberg as Director